腫瘤學為基礎的In-Vivo CRO的全球市場

Oncology Based In-Vivo CRO

出版日期: 2023年04月01日 | 出版商:

Global Industry Analysts, Inc. | 英文 93 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

腫瘤學為基礎的In-Vivo CRO的全球市場在2030年前將達到22億美元

在COVID-19後改變的商務環境中，2022年11億美元的腫瘤學為基礎的In-Vivo CRO的全球市場，2030年之前達到22億美元的規模，在2022年～2030年預計將以年複合成長率8.7％增長。本報告所分析之市場區隔之一的固體癌年複合成長率將記錄8.7％，到分析期間結束時將達到11億美元。考慮疫情後的復甦，血癌領域今後8年的年複合成長率將修正為7.2％。

美國市場估算為3億3,130萬美元，中國則將以年複合成長率8.2％增長

美國的腫瘤學為基礎的In-Vivo CRO市場在2022年估算為3億3,130萬美元。作為世界第2大經濟大國的中國，在2022年～2030年年複合成長率預計將為8.2％，在2030年達到3億8,350萬美元的市場規模。其他熱門的地區市場有日本和加拿大，在2022年～2030年預計將各以8.1％和6.9％的速度成長。在歐洲市場中，德國以年複合成長率約6.9％成長。

調查對象企業範例

Champion Oncology, Inc.
Charles River Laboratory
Covance
Crown Bioscience
Eurofins Scientific
EVOTEC
ICON Plc
Living Tumor Laboratory
MI Bioresearch, Inc.
Taconic Biosciences
The Jackson Laboratory
Wuxi AppTec
Xentech

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Oncology Based In-Vivo CRO Market to Reach $2.2 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Oncology Based In-Vivo CRO estimated at US$1.1 Billion in the year 2022, is projected to reach a revised size of US$2.2 Billion by 2030, growing at aCAGR of 8.7% over the period 2022-2030. Solid Tumors, one of the segments analyzed in the report, is projected to record 8.7% CAGR and reach US$1.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Blood Cancer segment is readjusted to a revised 7.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $331.3 Million, While China is Forecast to Grow at 8.2% CAGR

The Oncology Based In-Vivo CRO market in the U.S. is estimated at US$331.3 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$383.5 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 6.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.9% CAGR.

Select Competitors (Total 42 Featured) -

Champion Oncology, Inc.
Charles River Laboratory
Covance
Crown Bioscience
Eurofins Scientific
EVOTEC
ICON Plc
Living Tumor Laboratory
MI Bioresearch, Inc.
Taconic Biosciences
The Jackson Laboratory
Wuxi AppTec
Xentech

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Oncology Based In-Vivo CRO - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 2: World Historic Review for Oncology Based In-Vivo CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 3: World 16-Year Perspective for Oncology Based In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 5: World Historic Review for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 6: World 16-Year Perspective for Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 8: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 9: World 16-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 11: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 12: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- TABLE 13: World Oncology Based In-Vivo CRO Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
- Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- TABLE 14: USA Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 15: USA Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 16: USA 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
CANADA
- TABLE 17: Canada Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 18: Canada Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 19: Canada 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
JAPAN
- Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- TABLE 20: Japan Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 21: Japan Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 22: Japan 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
CHINA
- Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- TABLE 23: China Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 24: China Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 25: China 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
EUROPE
- Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- TABLE 26: Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 27: Europe Historic Review for Oncology Based In-Vivo CRO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 28: Europe 16-Year Perspective for Oncology Based In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- TABLE 29: Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 31: Europe 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
FRANCE
- Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- TABLE 32: France Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 33: France Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 34: France 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
GERMANY
- Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- TABLE 35: Germany Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 36: Germany Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 37: Germany 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
ITALY
- TABLE 38: Italy Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 39: Italy Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 40: Italy 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
UNITED KINGDOM
- Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- TABLE 41: UK Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 42: UK Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 43: UK 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
REST OF EUROPE
- TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 45: Rest of Europe Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 46: Rest of Europe 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
ASIA-PACIFIC
- Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 48: Asia-Pacific Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 49: Asia-Pacific 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
REST OF WORLD
- TABLE 50: Rest of World Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 51: Rest of World Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 52: Rest of World 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030